Veronique D
- Biogen (NASDAQ:BIIB) said that its GAAP and non-GAAP Q3 EPS results would be negatively impacted by ($0.01) per share due to an acquired in-process research and development, upfront and milestone expense of ~$2M on a pre-tax basis.
- Acquired IPR&D expense